Date: November 01, 2022
Time: 10:00am (PDT), 1:00pm (EDT), 6:00pm (CET)
Litron laboratories developed the Pig-a gene mutation assay as a means to simply and reliably evaluate the potential mutagenicity of compounds. Commercially available from Litron Laboratories under the name MutaFlow, this method utilizes the endogenous phosphatidylinositol glycan class A gene found in most mammalian species as a reporter of gene mutation. During early development, the assay was challenged by the rare event nature of this analysis and the time and effort required to interrogate a sufficient number of events in order to reliably calculate a mutation frequency in peripheral red blood cells. Following the addition of labeling of cells with superparamagnetic beads and the use of immunomagnetic columns to focus analysis on the cells of interest, the sample throughput and number of events scored was dramatically increased.
This critical improvement facilitated the continued development and commercialization of the assay into a successful line of kits and services. Subsequent to additional work by Litron and others, the validation of the assay was deemed sufficient to submit for regulatory approval in the form of Test Guideline development by the Organization of Economic Cooperation and Development (OECD). The formal “Test Guideline 470 Mammalian Erythrocyte Pig-a Gene Mutation Assay” was adopted in June of this year and serves to establish the assay as applicable for regulatory safety submissions.
- The MutaFlow Assay is an endogenous gene mutation assay that can be readily integrated with existing animal studies performed for product safety assessment
- The ability to focus analysis on the rare mutation phenotype is made possible by the combination of immunomagnetic separation and flow cytometry
- The Pig-a assay is now supported by an OECD Test Guideline (TG470) to facilitate use under GLP in support of regulatory submissions
Webinars will be available for unlimited on-demand viewing after live event.